This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Santen Pharmaceutical Co., Ltd.
Drug Names(s): DE-109, rapamycin, Sirolimus
Description: Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus found in the soil of Easter Island. Structurally, sirolimus resembles tacrolimus and binds to the same intracellular binding protein or immunophilin known as FKBP-12. However, sirolimus has a novel mechanism of action. Whereas tacrolimus and cyclosporine block lymphokine (e.g., IL2) gene transcription , sirolimus acts later to blocks IL2-dependent T lymphocyte proliferation and the stimulation caused by cross-linkage of CD28, possibly by blocking activation of a kinase referred to as mammalian target of rapamycin or mTOR, a serine-threonine kinase that is important for cell cycle progression. Therefore, sirolimus is believed to act in synergy with cyclosporine (or tacrolimus) in suppressing the immune system.
Deal Structure: In May 2008, Santen acquired rights from MacuSight for the Japanese and Asian development and commercialization for all ophthalmic indications of sirolimus (DE-109).
Santen acquired global development, manufacturing and marketing rights ofsirolimus from MacuSight in June 2010.
Pink Sheet Weekly Trademark Review Nov. 5, 2013
Pink Sheet Weekly Trademark Review Aug. 20, 2013
Additional information available to subscribers only: